ArticleNeuro-oncology practice2025

Health-related quality of life in patients with progressive glioblastoma treated with combined bevacizumab and lomustine versus lomustine only: Secondary outcome of the randomized phase III EORTC 26101 study.

Linda Dirven et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.